Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Extraction And Manufacturing Methods For Pure Cannabinoid Molecules Successfully Achieved

By Medical Marijuana, Inc. and Axim Biotechnologies, Inc. | March 2, 2018

Axim Biotech announces first-ever successful achievement of proprietary cGMP extraction and manufacturing methods for pure cannabinoid molecules.

Axim Biotechnologies, a major investment company in Medical Marijuana, Inc., has successfully executed its first-ever proprietary current good manufacturing practices (cGMP) methodology in the extraction and microencapsulation of cannabinoid molecules for a variety of pharmaceutical delivery formats from cGMP-produced medicinal cannabis. 

The breakthrough makes AXIM the only company in the world with the ability to harness the proprietary procedure and provide active pharmaceutical ingredients (APIs) of such purity from naturally extracted cGMP sources.

AXIM’s new methods are unprecedented in terms of the nature of the process—which utilizes cGMP standards employed from the initial growing of the cannabis plants through extraction and manufacturing—leading to the highest of quality standards for APIs being met.

The process, which was developed and tested in the Netherlands under strict regulatory guidelines, involves the growing of selected cannabis plants at a cGMP facility followed by extraction of the cannabinoid molecules from cannabis flowers in an innovative process that employs just two steps in order to achieve an average of more than 99% purity—unlike traditional methods that include toxic solvents and multiple steps to produce the final extract or synthesize an API such as dronabinol.

AXIM’s newly developed microencapsulation method is then applied to the cannabinoids, protecting those from oxidation and degradation, while preserving its effectiveness. AXIM’s microencapsulated cannabinoids then are manufactured into pharmaceutical products within different delivery formats.


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE